By PETER ROST
LOS ANGELES TIMES
The U.S. health-care system is the best in the world. Or so we are often told. But is it really true?
It is certainly the best system for drug companies, which can charge the highest prices in the world to some U.S. consumers. The Congressional Budget Office has estimated that average prices for patented drugs in 25 other top industrialized nations are 35 percent to 55 percent lower than in the United States.
And it is a pretty good system for hospitals, insurance companies and others that deliver health-care services. Americans spend about twice as much per person for health care as do Canadians, Japanese or Europeans, according to the World Health Organization.
But it's not a good system for American citizens. The United States has shorter life expectancies and higher infant and child mortality rates than Canada, Japan and all of Western Europe except Portugal, according to the WHO.
I'm a drug-company executive who has spent 20 years marketing pharmaceuticals. And I'm troubled. I'm most troubled by the fact that we stick it to the people who can afford it the least.
For instance, elderly people who use a Medicare discount card and have to pay $1,299 annually for a drug that the Department of Veterans Affairs purchases for $322, according to a comparison by Families USA. Or middle-class families that lose health insurance and have to pay $29,500 for an overnight hospital stay, when Medicaid would have paid only $6,000, according to The Wall Street Journal.
It just doesn't make any sense. And, not surprisingly, the companies with the biggest profits -- those in the drug industry -- have been fighting hardest to maintain the status quo.
Our dirty little secret is that the drug industry already sells its products, right here in the United States, at the same low prices charged in Canada and Europe. It's done through rebates. These are given to those with enough power to negotiate drug prices, such as the VA.
A 2001 study by the consumer advocacy group Public Citizen found that drug companies' favorite customers paid just a little over half the retail price. This leaves the 67 million Americans without insurance to pay cash, with no rebates, at double the prices paid by the most-favored customers.
The fight against re-importation of drugs is a fight to continue to charge our uninsureds full price while giving everyone else a rebate.
But what about all those programs drug companies provide to help the indigent pay for drugs? If they really worked, the Kaiser Family Foundation wouldn't have reported that 15 percent of uninsured children and 28 percent of uninsured adults had gone without prescription medication in 2000 because of cost, and 87 percent of uninsured individuals with serious health problems reported trouble obtaining medication.
People today have to choose between drugs and food. The journal Diabetes Care recently reported on a study of older adults with diabetes. One in three said they went without food to pay for drugs.
As a drug-company executive, I care about profits. When I was responsible for a region in Northern Europe, I doubled sales in two years by lowering drug prices, and in the process increased my company's sales ranking in Sweden from No. 19 to No. 7 in less than two years. I proved that it is possible to do good business with lower prices.
It's encouraging to see that the American Medical Association recently came out in favor of a system that would allow U.S. pharmacies and wholesalers to re-import drugs safely from other countries. This is exactly what Europe has had for more than 20 years. It is outrageous to claim, as politicians and drug companies have done, that the United States wouldn't be able to safely and cost-effectively handle re-importation.
In the next five years, branded drugs with annual sales of $72.9 billion are expected to lose patent protection. So we in the drug industry are fighting re-importation because we're worried about the bottom line.
I joined this industry to save lives, not to take them. And that's the reason I've chosen to speak out.
X Rost is a vice president of marketing at Pfizer; the views expressed here are his own, not those of his employer.